Mpox in 2023: Current Epidemiology and Management

AbstractPurpose of ReviewThe 2022 global mpox outbreak is a significant public health challenge. This review provides a summary of recent advancements in mpox phylogenetics, epidemiology, transmission, clinical presentation, treatment, and vaccination.Recent FindingsThe 2022 outbreak saw a shift in epidemiology, with human-to-human transmission, particularly among men who have sex with men (MSM), becoming the primary mode of spread. Among IIb.B.1 sequences, there is evidence for an emerging human-adapted monkeypox virus (MPXV). Antiviral treatments like tecovirimat have shown promise in severe cases. Two doses of the non-replicative 3rd generation vaccine MVA-BN provide better protection than a single dose.SummaryThis outbreak underscores the importance of global surveillance, prompt response, and effective vaccination strategies in managing emerging infectious diseases. Efforts to destigmatize the disease and increase awareness among high-risk populations are vital in curbing transmission. Continued research and international collaboration are essential for understanding the MPXV and improving preparedness for future outbreaks.
Source: Current Infectious Disease Reports - Category: Infectious Diseases Source Type: research